Amicus Therapeutics (FOLD) Short Interest Ratio & Short Volume $10.20 -0.17 (-1.64%) (As of 02:20 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Amicus Therapeutics Short Interest DataAmicus Therapeutics (FOLD) has a short interest of 19.90 million shares. This marks a -9.30% decrease in short interest from the previous month. The short interest ratio (days to cover) is 8.3, indicating that it would take 8.3 days of the average trading volume of 2.72 million shares to cover all short positions.Current Short Interest19,900,000 sharesPrevious Short Interest21,940,000 sharesChange Vs. Previous Month-9.30%Dollar Volume Sold Short$227.26 millionShort Interest Ratio8.3 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares298,810,000 sharesPercentage of Shares Shorted6.66%Today's Trading Volume995,858 sharesAverage Trading Volume2,720,262 sharesToday's Volume Vs. Average37% Short Selling Amicus Therapeutics? Sign up to receive the latest short interest report for Amicus Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartFOLD Short Interest Over TimeFOLD Days to Cover Over TimeFOLD Percentage of Float Shorted Over Time Ad Porter & CompanyElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Amicus Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/202419,900,000 shares $227.26 million -9.3%N/A8.3 $11.42 10/15/202421,940,000 shares $226.20 million +0.9%N/A8.4 $10.31 9/30/202421,740,000 shares $232.18 million -4.7%N/A8.4 $10.68 9/15/202422,810,000 shares $257.75 million -1.7%N/A8.7 $11.30 8/31/202423,200,000 shares $269.35 million -3.5%N/A9 $11.61 8/15/202424,040,000 shares $275.26 million -2.0%N/A9.1 $11.45 Get the Latest News and Ratings for FOLD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/202424,520,000 shares $252.80 million -5.2%N/A9 $10.31 7/15/202425,860,000 shares $274.89 million +0.1%N/A10.1 $10.63 6/30/202425,840,000 shares $256.33 million +0.2%N/A10.5 $9.92 6/15/202425,800,000 shares $261.61 million -6.5%N/A10.1 $10.14 5/31/202427,590,000 shares $270.38 million -4.6%N/A10.3 $9.80 5/15/202428,910,000 shares $279.27 million +0.5%N/A9.5 $9.66 4/30/202428,770,000 shares $287.41 million -8.1%N/A9.4 $9.99 4/15/202431,320,000 shares $333.87 million -3.6%N/A10.3 $10.66 3/31/202432,490,000 shares $382.73 million +0.3%N/A10.7 $11.78 3/15/202432,400,000 shares $371.95 million +4.8%N/A10.3 $11.48 2/29/202430,910,000 shares $396.27 million +15.4%N/A9.4 $12.82 2/15/202426,780,000 shares $374.92 million +9.8%N/A8.6 $14.00 1/31/202424,400,000 shares $303.29 million -2.6%N/A8.1 $12.43 1/15/202425,060,000 shares $330.29 million -2.7%N/A8.3 $13.18 12/31/202325,750,000 shares $365.39 million -4.3%N/A8.8 $14.19 12/15/202326,910,000 shares $342.30 million +11.5%N/A9.2 $12.72 11/30/202324,140,000 shares $266.02 million +6.2%N/A9.6 $11.02 11/15/202322,730,000 shares $242.30 million +0.8%N/A9.6 $10.66 10/31/202322,560,000 shares $247.48 million +0.4%N/A10 $10.97 10/15/202322,480,000 shares $234.69 million +19.1%N/A9.3 $10.44 9/30/202318,870,000 shares $229.46 million -0.2%N/A7.9 $12.16 9/15/202318,900,000 shares $247.40 million -3.8%N/A8.6 $13.09 8/31/202319,640,000 shares $251.78 million +3.1%N/A8.5 $12.82 8/15/202319,050,000 shares $247.46 million -16.6%N/A7.9 $12.99 7/31/202322,830,000 shares $310.94 million +13.3%N/A8.2 $13.62 7/15/202320,150,000 shares $270.01 million -6.5%N/A7.9 $13.40 6/30/202321,540,000 shares $270.54 million +10.0%N/A8.7 $12.56 6/15/202319,580,000 shares $253.76 million +2.4%N/A7.6 $12.96 5/31/202319,120,000 shares $215.29 million -10.2%N/A7.6 $11.26 5/15/202321,300,000 shares $238.56 million -1.1%N/A8.7 $11.20 4/30/202321,530,000 shares $248.46 million +2.2%N/A9.8 $11.54 4/15/202321,060,000 shares $240.08 million +5.4%N/A9.9 $11.40 3/31/202319,980,000 shares $221.58 million -4.3%N/A8.9 $11.09 3/15/202320,880,000 shares $238.66 million +15.4%N/A9.8 $11.43The next assassination attempt won’t be on Trump (Ad)President Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.I share with you in this special investigative documentary. 2/28/202318,090,000 shares $238.61 million +0.2%N/A8.6 $13.19 2/15/202318,060,000 shares $236.77 million -8.1%N/A8.8 $13.11 1/31/202319,650,000 shares $256.24 million +1.5%N/A9.3 $13.04 1/15/202319,370,000 shares $248.52 million -3.8%N/A8.5 $12.83 12/30/202220,140,000 shares $245.91 million +12.6%N/A9.2 $12.21 12/15/202217,880,000 shares $216.17 million -12.0%N/A7.8 $12.09 11/30/202220,310,000 shares $245.75 million +7.6%N/A8.3 $12.10 11/15/202218,880,000 shares $220.33 million +3.4%N/A7.4 $11.67 10/31/202218,260,000 shares $182.60 million -12.1%N/A7.1 $10.00 10/15/202220,780,000 shares $220.27 million +2.3%N/A7.8 $10.60 9/30/202220,310,000 shares $212.04 million -8.5%N/A7.3 $10.44 9/15/202222,200,000 shares $243.09 million +2.5%N/A7.4 $10.95 8/31/202221,660,000 shares $243.24 million +13.2%N/A6.9 $11.23 8/15/202219,130,000 shares $236.64 million -5.2%N/A5.8 $12.37 7/31/202220,170,000 shares $200.89 million -7.3%N/A5.4 $9.96 7/15/202221,750,000 shares $235.99 million -18.5%N/A5.6 $10.85 6/30/202226,700,000 shares $286.76 million -10.8%N/A7 $10.74 6/15/202229,930,000 shares $245.13 million -4.2%N/A7.5 $8.19 5/31/202231,240,000 shares $238.05 million +8.2%N/A8.2 $7.62 5/15/202228,880,000 shares $216.31 million +6.3%N/A7.7 $7.49 4/30/202227,170,000 shares $192.36 million -3.3%N/A8 $7.08 4/15/202228,090,000 shares $230.06 million +1.3%N/A9.4 $8.19 3/31/202227,720,000 shares $262.51 million -1.8%N/A8.6 $9.47 3/15/202228,220,000 shares $252.57 million +2.7%N/A9.7 $8.95 2/28/202227,490,000 shares $223.77 million +3.0%N/A10.1 $8.14 2/15/202226,680,000 shares $255.06 million +3.7%N/A10.5 $9.56 1/31/202225,720,000 shares $242.03 million +6.8%N/A10 $9.41 1/15/202224,080,000 shares $253.56 million -7.6%N/A9.6 $10.53 12/31/202126,070,000 shares $301.11 million +4.0%N/A10.8 $11.55 12/15/202125,060,000 shares $266.89 million -0.1%N/A10.1 $10.65 11/30/202125,080,000 shares $268.61 million +2.8%N/A10.2 $10.71 11/15/202124,390,000 shares $280.73 million -15.8%N/A10 $11.51 10/29/202128,970,000 shares $304.19 million -2.4%11.1%12.5 $10.50 10/15/202129,670,000 shares $328.74 million +5.4%11.3%12.7 $11.08 9/30/202128,140,000 shares $268.74 million +4.7%10.8%11.6 $9.55 9/15/202126,880,000 shares $299.44 million -2.2%10.3%12.8 $11.14 8/31/202127,490,000 shares $313.11 million -1.5%10.5%13.2 $11.39 8/13/202127,910,000 shares $292.50 million -3.6%10.7%12 $10.48 7/30/202128,960,000 shares $269.04 million -2.4%11.1%11.9 $9.29 7/15/202129,660,000 shares $270.80 million -1.0%11.4%12.3 $9.13 6/30/202129,970,000 shares $288.91 million +5.0%11.5%12.3 $9.64 6/15/202128,550,000 shares $295.49 million -6.7%10.9%10.9 $10.35 5/28/202130,600,000 shares $283.36 million -4.9%11.7%11.3 $9.26 5/14/202132,180,000 shares $301.53 million +8.1%N/A10.4 $9.37 4/30/202129,760,000 shares $296.71 million -7.2%N/A7.5 $9.97 4/15/202132,050,000 shares $319.86 million -3.3%N/A7.9 $9.98 3/31/202133,150,000 shares $311.28 million +3.7%N/A8.1 $9.39 3/15/202131,960,000 shares $344.53 million -0.3%N/A8 $10.78 2/26/202132,060,000 shares $382.16 million +3.1%N/A8.1 $11.92 2/12/202131,100,000 shares $582.50 million -2.0%N/A8.6 $18.73The next assassination attempt won’t be on Trump (Ad)President Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.I share with you in this special investigative documentary. 1/29/202131,720,000 shares $612.20 million +16.4%N/A12.3 $19.30 1/15/202127,250,000 shares $634.65 million -8.2%N/A10.9 $23.29 12/31/202029,690,000 shares $681.09 million -10.4%N/A12.5 $22.94 12/15/202033,120,000 shares $790.91 million +13.3%N/A14.2 $23.88 11/30/202029,240,000 shares $679.54 million -3.7%N/A13.3 $23.24 11/15/202030,360,000 shares $667.31 million +4.0%N/A15.3 $21.98 10/30/202029,200,000 shares $535.82 million -0.7%N/A15.2 $18.35 10/15/202029,390,000 shares $482.00 million -1.5%11.6%15.6 $16.40 9/30/202029,830,000 shares $421.20 million -1.3%11.8%15 $14.12 9/15/202030,230,000 shares $420.50 million -0.9%11.9%14.4 $13.91 8/31/202030,490,000 shares $445.15 million -0.1%12.0%12.4 $14.60 8/14/202030,530,000 shares $439.63 million -1.7%12.0%11.3 $14.40 7/31/202031,070,000 shares $448.96 million -2.8%12.3%10.5 $14.45 7/15/202031,960,000 shares $480.68 million -3.4%12.7%10.4 $15.04 6/30/202033,070,000 shares $513.91 million +3.7%13.1%10.7 $15.54 6/15/202031,900,000 shares $348.67 million -1.2%12.7%9.8 $10.93 5/29/202032,280,000 shares $402.69 million -0.1%12.8%9.6 $12.48 5/15/202032,310,000 shares $359.93 million -5.5%12.8%9.3 $11.14 4/30/202034,200,000 shares $419.29 million -3.9%13.6%10.1 $12.26 4/15/202035,570,000 shares $356.77 million +0.3%14.2%10.2 $10.03 3/31/202035,450,000 shares $454.47 million -2.0%14.1%10 $12.82 3/13/202036,154,700 shares $376.37 million -2.6%14.4%10.6 $10.41 2/28/202037,110,000 shares $322.86 million +1.8%14.8%11.2 $8.70 2/14/202036,460,000 shares $326.68 million -3.8%14.7%11.4 $8.96 1/31/202037,900,000 shares $373.32 million +5.4%15.3%11.6 $9.85 1/15/202035,950,000 shares $385.38 million +8.1%14.5%11.5 $10.72 12/31/201933,260,000 shares $297.34 million +4.8%13.4%10.8 $8.94 FOLD Short Interest - Frequently Asked Questions What is Amicus Therapeutics' current short interest? Short interest is the volume of Amicus Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 19,900,000 shares of FOLD short. Learn More on Amicus Therapeutics' current short interest. What is a good short interest ratio for Amicus Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FOLD shares currently have a short interest ratio of 8.0. Learn More on Amicus Therapeutics's short interest ratio. Which institutional investors are shorting Amicus Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Amicus Therapeutics: Walleye Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Amicus Therapeutics' short interest increasing or decreasing? Amicus Therapeutics saw a decline in short interest in October. As of October 31st, there was short interest totaling 19,900,000 shares, a decline of 9.3% from the previous total of 21,940,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Amicus Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Amicus Therapeutics: Bausch Health Companies Inc. (3.59%), Perrigo Company plc (3.64%), Arrowhead Pharmaceuticals, Inc. (7.55%), Biohaven Ltd. (9.68%), BridgeBio Pharma, Inc. (11.71%), Allakos Inc. (1.91%), Blueprint Medicines Co. (6.50%), BioMarin Pharmaceutical Inc. (2.82%), Neurocrine Biosciences, Inc. (2.45%), Exelixis, Inc. (3.28%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Amicus Therapeutics stock? Short selling FOLD is an investing strategy that aims to generate trading profit from Amicus Therapeutics as its price is falling. FOLD shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Amicus Therapeutics? A short squeeze for Amicus Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of FOLD, which in turn drives the price of the stock up even further. How often is Amicus Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FOLD, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Bausch Health Companies Short Interest Perrigo Short Interest Arrowhead Pharmaceuticals Short Interest Biohaven Short Interest BridgeBio Pharma Short Interest Allakos Short Interest Blueprint Medicines Short Interest BioMarin Pharmaceutical Short Interest Neurocrine Biosciences Short Interest Exelixis Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:FOLD) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FOLD Stock Alerts